IN2014MN02382A - - Google Patents

Info

Publication number
IN2014MN02382A
IN2014MN02382A IN2382MUN2014A IN2014MN02382A IN 2014MN02382 A IN2014MN02382 A IN 2014MN02382A IN 2382MUN2014 A IN2382MUN2014 A IN 2382MUN2014A IN 2014MN02382 A IN2014MN02382 A IN 2014MN02382A
Authority
IN
India
Prior art keywords
shc
symptoms
medicament
treating
manufacture
Prior art date
Application number
Other languages
English (en)
Inventor
Shau Feng Chang
Chun Hsien Ma
Kuo Yi Yang
Original Assignee
Ind Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Tech Res Inst filed Critical Ind Tech Res Inst
Publication of IN2014MN02382A publication Critical patent/IN2014MN02382A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IN2382MUN2014 2012-12-26 2013-05-14 IN2014MN02382A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/727,387 US20140179774A1 (en) 2012-12-26 2012-12-26 Methods for inhibition of shc-1/p66 to combat aging-related diseases
PCT/CN2013/075599 WO2014101366A1 (en) 2012-12-26 2013-05-14 Methods for inhibition of shc-1/p66 to combat aging-related diseases

Publications (1)

Publication Number Publication Date
IN2014MN02382A true IN2014MN02382A (de) 2015-08-14

Family

ID=50975338

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2382MUN2014 IN2014MN02382A (de) 2012-12-26 2013-05-14

Country Status (8)

Country Link
US (1) US20140179774A1 (de)
EP (1) EP2838528A4 (de)
JP (1) JP6305422B2 (de)
KR (2) KR20170027860A (de)
CN (1) CN104487069A (de)
IN (1) IN2014MN02382A (de)
SG (1) SG11201407425SA (de)
WO (1) WO2014101366A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026441A1 (en) * 2016-08-01 2018-02-08 The Regents Of The University Of California Methods for preventing or treating fibrotic diseases
CN117379635A (zh) 2019-05-30 2024-01-12 贝克顿·迪金森公司 用于药物递送装置的药筒适配器
KR20230083169A (ko) 2021-12-02 2023-06-09 대주전자재료 주식회사 다공성 규소-탄소 복합체, 이의 제조방법 및 이를 포함하는 음극 활물질

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2230573T3 (es) 1995-12-26 2005-05-01 Suntory Limited Agente anti-obesidad cuyo principio activo es la procianidina.
JPH09291039A (ja) * 1995-12-26 1997-11-11 Suntory Ltd プロシアニジンを有効成分とする抗肥満剤
GB9906515D0 (en) * 1999-03-22 1999-05-19 Europ I Of Oncology Materials and methods relating to the effects oF P66 expression
US6495593B1 (en) * 1999-06-18 2002-12-17 Dry Creek Nutrition, Inc. Compositions for preventing or treating adverse physiological effects associated with cardiac disease
KR100509119B1 (ko) 1999-07-16 2005-08-18 주식회사 엘지생활건강 프로시아니딘 올리고머를 유효성분으로 하는 약제
NZ528322A (en) * 2001-03-15 2005-03-24 Proteotech Inc Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases such as alzheimer's disease and parkinson's
EP1256335A1 (de) * 2001-05-10 2002-11-13 Cognis France S.A. Verwendung von oligomeren Procyanolidinen
CN1443533A (zh) * 2002-03-07 2003-09-24 程彦杰 原花青素类化合物在用于制备解酒保肝产品方面的用途
KR100531472B1 (ko) * 2002-08-09 2005-11-28 주식회사 이롬 항산화 활성을 가지는 찔레나무 추출물을 포함하는 화장품 조성물 및 상기 추출물의 제조방법
JP2006232670A (ja) * 2003-05-20 2006-09-07 Ajinomoto Co Inc 神経障害用薬剤
JP2005097273A (ja) * 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
US20080044453A1 (en) 2003-09-26 2008-02-21 Kirin Beer Kabushiki Kaisha Therapeutic Agent for Treatment of Autoimmune Diseases
CN100586431C (zh) * 2007-09-28 2010-02-03 天津市尖峰天然产物研究开发有限公司 原花青素b2在制备防治糖尿病及血管并发症药物的应用
TWI370736B (en) 2008-12-31 2012-08-21 Ind Tech Res Inst Pharmaceutical composition for treating hepatitis b and heath food for inhibiting hepatitis b virus
US20130123204A1 (en) * 2008-12-31 2013-05-16 Industrial Technology Research Institute Method for treating hepatitis b
CN101822372A (zh) * 2009-03-05 2010-09-08 财团法人工业技术研究院 用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品
CN102480951A (zh) * 2009-04-17 2012-05-30 卡迪罗治疗公司 用于治疗局部缺血病症和与线粒体功能相关病症的方法和组合物
TWI458487B (zh) 2009-12-30 2014-11-01 Ind Tech Res Inst 藥學組合物之用途
JP2011178728A (ja) * 2010-03-02 2011-09-15 Kobe Univ Ａｍｐｋ活性化剤、ｇｌｕｔ４活性化剤、およびそれらを用いた医薬品・飲食品
PL2689777T3 (pl) * 2011-03-22 2018-08-31 Industrial Technology Research Institute Kompozycja farmaceutyczna do pobudzania regeneracji wątroby
WO2012163588A2 (en) * 2011-05-27 2012-12-06 Unilever Plc Anti-ageing composition
US9187448B2 (en) * 2011-08-05 2015-11-17 Cardero Therapeutics, Inc. Flavonoid compounds
JP5813576B2 (ja) * 2012-05-22 2015-11-17 アピオン・ジャパン有限会社 サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤
CN102688230B (zh) * 2012-06-20 2014-12-03 浙江萧山医院 原花青素b2的用途
CN102688501A (zh) * 2012-06-20 2012-09-26 浙江萧山医院 原花青素b2磷脂复合物及其制备方法和用途
US20150336981A1 (en) * 2012-11-08 2015-11-26 Cellarouge Pty Ltd Modified polyphenols and modified polyphenol compositions

Also Published As

Publication number Publication date
WO2014101366A1 (en) 2014-07-03
KR20170027860A (ko) 2017-03-10
JP2016502532A (ja) 2016-01-28
JP6305422B2 (ja) 2018-04-04
EP2838528A4 (de) 2015-09-09
SG11201407425SA (en) 2014-12-30
CN104487069A (zh) 2015-04-01
KR20150013629A (ko) 2015-02-05
EP2838528A1 (de) 2015-02-25
US20140179774A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
BR112015026325A2 (pt) dosagem oral de compostos glp-1
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2021004211A (es) Composiciones vacuna.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
WO2013098416A3 (fr) Composes anti-douleur
IN2015DN00515A (de)
MX2015008187A (es) Inhibidores de alk deuterados.
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
HK1203054A1 (en) Dinuceloside polyphosphates for the treatment of pain
EP4385563A3 (de) Dosierungsformen und therapeutische verwendungen von l-4-chlorkynurenin
IN2015DN02358A (de)
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
PH12014502065A1 (en) Vesicular formulations
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
IN2014MN02382A (de)
ITRM20120405A1 (it) Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
EP2841077A4 (de) Nährstofffaserzusammensetzungen zur behandlung von stoffwechselstörungen
IN2014KN01772A (de)
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
EP2854539A4 (de) Phosphonatderivate zur behandlung von morbus alzheimer
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης